About

Adovate is a pharmaceutical company developing novel drugs targeting adenosine receptors, which are involved in major diseases. These best-in-class drug candidates have been created using our adenosine drug development platform, which has enabled us to design patentable compounds with favorable physiochemical characteristics (e.g., potency, selectivity, biodistribution) to overcome issues that historically that historically limited the targeting of adenosine receptors. This platform is the cornerstone of our company and confers a competitive advantage that will allow us to broaden our future drug pipeline efficiently and economically.

Adovate’s technology has been in development since 2019 and was acquired by Adovate in 2023. We invent and develop our own propriety and patentable compounds. The pharmacology of our targets is understood, however, our compounds overcome the liabilities of previous drug development efforts. This significantly reduces the risks of the programs we have chosen for development.